LeMaitre Vascular (LMAT) Expected to Announce Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT) is expected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.57 per share and revenue of $62.18 million for the quarter. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS.Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $62.48 million. During the same period in the previous year, the company earned $0.52 earnings per share. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Trading Down 0.7%

NASDAQ:LMAT opened at $88.87 on Thursday. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 43.14, a PEG ratio of 2.31 and a beta of 0.77. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The company’s 50 day moving average price is $90.94 and its 200-day moving average price is $86.94. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $109.58.

Insider Activity

In related news, Director Bridget A. Ross sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares of the company’s stock, valued at $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 120,815 shares of company stock valued at $11,280,206 in the last 90 days. Company insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after purchasing an additional 55,804 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of LeMaitre Vascular by 14.1% during the second quarter. Ameriprise Financial Inc. now owns 231,282 shares of the medical instruments supplier’s stock valued at $19,208,000 after buying an additional 28,556 shares during the last quarter. Millennium Management LLC boosted its stake in LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in shares of LeMaitre Vascular by 7.0% during the second quarter. Qube Research & Technologies Ltd now owns 173,839 shares of the medical instruments supplier’s stock valued at $14,437,000 after buying an additional 11,416 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of LeMaitre Vascular by 30.5% during the 2nd quarter. Bank of America Corp DE now owns 115,263 shares of the medical instruments supplier’s stock valued at $9,573,000 after acquiring an additional 26,966 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Barrington Research reiterated an “outperform” rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Finally, Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.